Phil Carroll and Kevin Hornsby talk to Allan about CIZ1b. Primary lung cancer is the leading cause of cancer deaths worldwide. Early detection is crucial, as surgical resection of early-stage tumors is the only curative therapy currently available. Lung cancers detected at stage 1 have a better outcome than those diagnosed later. Screening programs using chest X-ray or low-dose computed tomography can identify the disease at an early stage, but the costs of screening, including the high number of false positives, make stand-alone imaging strategies difficult to justify. A blood-based biomarker, CIZ1b, has shown promise in detecting early-stage lung cancer. Shaun Day makes an appearance and talks about the recent Scallyway results and his time in London. As usual, there is a weekly round-up of the movers and shakers and a look at the biggest news stories of the past week.
Disclaimer & Declaration of Interest
The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion
View all episodes
